SIC
CLDX icon

Salem Investment Counselors’s Celldex Therapeutics CLDX Stock Holding History

Salem Investment Counselors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-33
Closed -$1K – 525
2017
Q4 		$1K Hold
33
– – ﹤0.01% 535
2017
Q3 		$1K Sell
33
-37
-53% -$1.39K ﹤0.01% 537
2017
Q2 		$3K Buy
+70
New +$3.1K ﹤0.01% 545
2017
Q1 		– Sell
-70
Closed -$4K – 559
2016
Q4 		$4K Hold
70
– – ﹤0.01% 550
2016
Q3 		$42 Sell
70
-1,563
-96% -$97.3K ﹤0.01% 453
2016
Q2 		$108K Sell
1,633
-34
-2% -$2.16K 0.01% 247
2016
Q1 		$95K Buy
1,667
+34
+2% +$3.83K 0.01% 245
2015
Q4 		$384K Buy
1,633
+184
+13% +$40.1K 0.05% 191
2015
Q3 		$227K Sell
1,449
-20
-1% -$5.66K 0.03% 241
2015
Q2 		$556K Sell
1,469
-80
-5% -$31.8K 0.07% 178
2015
Q1 		$648K Hold
1,549
– – 0.08% 176
2014
Q4 		$424K Sell
1,549
-714
-32% -$178K 0.05% 200
2014
Q3 		$440K Sell
2,263
-123
-5% -$26.8K 0.05% 200
2014
Q2 		$584K Sell
2,386
-423
-15% -$95.5K 0.07% 180
2014
Q1 		$745K Sell
2,809
-152
-5% -$58.2K 0.09% 162
2013
Q4 		$1.07M Hold
2,961
– – 0.14% 136
2013
Q3 		$1.57M Hold
2,961
– – 0.22% 103
2013
Q2 		$693K Buy
+2,961
New +$583K 0.1% 157

Other funds holding CLDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Salem Investment Counselors's CLDX Position: Q1 2018 in Review

Salem Investment Counselors sold out of Celldex Therapeutics (CLDX) in Q1 2018, closing a stake of 33 shares — an estimated $1K sold.

Salem Investment Counselors first reported a position in CLDX in Q2 2013 and held it in 18 quarters. The position peaked at $1.57M in Q3 2013. 131 funds tracked by Wall St. Rank hold CLDX as of Q1 2018.

  • Salem Investment Counselors reported no remaining Celldex Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Salem Investment Counselors sold 33 Celldex Therapeutics shares in Q1 2018, an estimated $1K.
  • Salem Investment Counselors first reported a position in Celldex Therapeutics in Q2 2013 and held it in 18 quarters.
  • Salem Investment Counselors's Celldex Therapeutics position peaked at $1.57M in Q3 2013.
  • 131 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2018.

Based on Salem Investment Counselors's 13F filing for Q1 2018, filed 15 May 2018.